| 崔 东,孙立立,张 旭,张大红,刘 君.沙库巴曲缬沙坦钠对老年慢性心力衰竭合并2型糖尿病患者肾功能、神经内分泌激素和TGF-β1/Smad3信号通路的影响[J].,2023,(16):3102-3106 |
| 沙库巴曲缬沙坦钠对老年慢性心力衰竭合并2型糖尿病患者肾功能、神经内分泌激素和TGF-β1/Smad3信号通路的影响 |
| Effects of Sacubitril Valsartan Sodium on Renal Function, Neuroendocrine Hormone and TGF-?茁1/Smad3 Signaling Pathway in Elderly Patients with Chronic Heart Failure Complicated with Type 2 Diabetes Mellitus |
| 投稿时间：2023-03-13 修订日期：2023-03-31 |
| DOI：10.13241/j.cnki.pmb.2023.16.020 |
| 中文关键词: 沙库巴曲缬沙坦钠 老年 慢性心力衰竭 2型糖尿病 肾功能 神经内分泌激素 TGF-β1/Smad3信号通路 |
| 英文关键词: Sacubitril Valsartan sodium Elderly Chronic heart failure Type 2 diabetes mellitus Renal function Neuroendocrine hormone TGF- β1/Smad3 signaling pathway |
| 基金项目:河北省医学科学研究课题计划项目（20211711） |
|
| 摘要点击次数: 419 |
| 全文下载次数: 296 |
| 中文摘要: |
| 摘要 目的：探讨沙库巴曲缬沙坦钠对老年慢性心力衰竭（CHF）合并2型糖尿病（T2DM）患者肾功能、神经内分泌激素和转化生长因子-β1（TGF-β1）/Smad3信号通路的影响。方法：选择我院2020年5月~2021年5月期间收治的92例老年CHF合并T2DM患者，按照双色球法将患者分为对照组（n=46，接受常规治疗）和研究组（n=46，对照组基础上接受沙库巴曲缬沙坦钠治疗）。对比两组心功能、肾功能、神经内分泌激素、TGF-β1/Smad3信号通路相关指标和不良反应发生情况。结果：治疗12个月后，研究组心输出量（CO）、左心室射血分数（LVEF）高于对照组，左心室舒张末期内径（LVEDD）低于对照组（P<0.05）。治疗12个月后，研究组血肌酐（Scr）、血尿素氮（BUN）、血尿酸（UA）、中性粒细胞明胶酶相关脂质运载蛋白（NGAL）、胱抑素C（Cys-C）低于对照组（P<0.05）。治疗12个月后，研究组去甲肾上腺素（NE）、醛固酮（ALD）和血管紧张素II（AngII）低于对照组（P<0.05）。治疗12个月后，研究组Smad7 mRNA高于对照组，Smad2 mRNA、TGF-β1 mRNA、Smad3 mRNA低于对照组（P<0.05）。两组不良反应发生率组间比较差异无统计学意义（P>0.05）。结论：沙库巴曲缬沙坦钠用于治疗老年CHF合并T2DM患者，可有效改善患者的心功能、肾功能、神经内分泌激素和TGF-β1/Smad3信号通路相关指标，安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Sacubitril Valsartan sodium on renal function, neuroendocrine hormone and transforming growth factor-β1 (TGF-β1) /Smad3 signaling pathway in elderly patients with chronic heart failure (CHF) complicated with type 2 diabetes mellitus (T2DM). Methods: 92 elderly patients with CHF complicated with T2DM who were admitted to our hospital from May 2020 to May 2021 were selected, and they were divided into control group (n=46, receiving conventional treatment) and study group (n=46, receiving Sacubitril Valsartan sodium treatment on the basis of control group) according to dichromatic sphere method. Cardiac function, renal function, neuroendocrine hormone, TGF-β1/Smad3 signaling pathway related indicators and the occurrence of adverse reactions were compared in the two groups. Results: 12 months after treatment, the cardiac output (CO) and left ventricular ejection fraction (LVEF) in the study group were higher than those in the control group, and the left ventricular end-diastolic diameter (LVEDD) was lower than that in the control group (P<0.05). 12 months after treatment, serum creatinine (Scr), blood urea nitrogen (BUN), blood uric acid (UA), neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (Cys-C) in the study group were lower than those in the control group (P<0.05). 12 months after treatment, norepinephrine (NE), aldosterone (ALD) and angiotensin II (AngII) in the study group were lower than those in the control group(P<0.05). 12 months after treatment, Smad7 mRNA in the study group was higher than that in the control group, while Smad2 mRNA, TGF-β1 mRNA and Smad3 mRNA were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups (P>0.05). Conclusion: Sacubitril Valsartan sodium is used to treat elderly patients with CHF complicated with T2DM, which can effectively improve the cardiac function, renal function, neuroendocrine hormone and TGF-β1/Smad3 signaling pathway related indicators, with a good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
